---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-001609"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:35:00.407397+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma hires Aegis Capital as warrant solicitation agent for 3 months, 10% fee on proceeds

## Summary
- Engaged Aegis Capital on March 6, 2026 to induce exercise of outstanding warrants on best-efforts basis.
- Term of engagement agreement is three months; Aegis receives 10% of gross proceeds from warrant exercises.
- Company agreed to reimburse Aegis up to $100,000 for legal fees and expenses.
- Engagement includes exclusivity provision: Company cannot solicit other financing during term except existing debt holders.
- Warrants trade under ticker SBFMW on Nasdaq; proceeds would provide non-dilutive capital to the company.

## SEC filing metadata
- accession: 0001683168-26-001609
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316826001609/0001683168-26-001609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316826001609/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-001609
- JSON: https://secwatch.observer/filing/0001683168-26-001609.json
- Plain text: https://secwatch.observer/filing/0001683168-26-001609.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.